# MASTER-2026-11 final review

| Field | Value |
|---|---|
| Date | 2026-11-05 |
| Reviewer | Claude (MASTER-2026-11 watcher) |
| Scope | `codex/living-docs-master-2026-11-status` at `0aa7de1` (PR #16): `reports/phases/MASTER-2026-11-status.md` plus living docs |
| Verdict | **APPROVED**, merged. **MASTER-2026-11 is complete.** |

## Verification

- Documentation only; no `src/`, `config/`, `scripts/` or test bytes. It merges cleanly onto `6848cc3`.
- All ten cited merge commits (`ed40682`, `f3ca5a7`, `85273ef`, `8034d3b`, `f00b95e`, `5b4df01`, `18c7bf4`, `89bc63e`, `1f5fa42`, `6848cc3`) are confirmed ancestors of `main`.
- The verdict tables match the approved reviews: F 0 pass, 7 fail, 2 insufficient; G 1 reject, 0 promising, 2 insufficient; K acquisition complete, validation skipped.
- The final gate (1,772 passed, 0 xfailed) matches my independent K gate. The risk defaults, the 2025+ holdout, the sealed archive and the no-orders boundary are all unchanged.

## Outcome

The platform work is complete:
- clean five-instrument history;
- the Treasury yield context;
- the venue-status veto;
- all audit findings fixed (the environmental S-5 owner ACL item remains for the owner);
- reliable gates;
- the live sealed XAUT capture.

**No pre-registered intraday strategy shows an edge after realistic costs.** About 0.38% per XAUT round trip is comparable to typical intraday stops.

## Owner decisions (not authorized by this batch)

1. Research direction: longer holding periods (needs an `AGENTS.md` rule change), new high-move intraday hypotheses (fresh pre-registration and trial accounting), or pause.
2. Stage 4/5, paper trading, Testnet, orders: separate scope only.
3. Operator items: the `.env` ACL, collector boot recovery privileges, and P14 rights/release.
